<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04289727</url>
  </required_header>
  <id_info>
    <org_study_id>AAAS5630</org_study_id>
    <nct_id>NCT04289727</nct_id>
  </id_info>
  <brief_title>Skeletal Fragility in Type 1 Diabetes: Glycemic Control and Bone Strength</brief_title>
  <official_title>Skeletal Fragility in Type 1 Diabetes: Glycemic Control and Bone Strength</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to find out how bones are affected in children and
      adolescents with type 1 diabetes (T1D) as compared to children and adolescents without type 1
      diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      T1D is primarily associated with decrements in bone strength due to disrupted
      microarchitecture occurring during peak bone mass accrual, and this disruption arises from
      hyperglycemia and glycemic variability. Impaired bone development during this period likely
      predisposes to an increased fracture risk across the lifespan.

      The investigators will compare baseline, 12 month and 24 month changes in High-resolution
      peripheral quantitative computed tomography/micro-finite element analysis
      (HR-pQCT/μFEA)-based estimates of bone strength and bone turnover by biochemical measurements
      in 40 T1D children at the onset of peak bone mineral accretion (n=40) versus sex and
      puberty-matched healthy controls (n=40). The investigators will determine relationships
      between changes in bone strength (including trabecular and cortical components) and measures
      of glycemic control and variability by continuous glucose monitoring (CGM).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in microarchitecture by HR-pQCT</measure>
    <time_frame>Two Years</time_frame>
    <description>Measures of HRpQCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in bone mineral density by Dual X-ray Absorptometry (DXA)</measure>
    <time_frame>Two Years</time_frame>
    <description>Measures of DXA</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Type1diabetes</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Those with Type 1 Diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Those without Type 1 Diabetes.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      am fasting Comprehensive Metabolic Panel (CMP) including liver function, HbA1c and 25OHD.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        40 children and adolescents between the age of 8 to 14 years with type 1 diabetes and 40
        children and adolescents between the age of 8 to 14 years without type 1 diabetes.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (T1D and Controls):

        - Children within 2 years preceding the onset of the pubertal growth spurt

        Inclusion Criteria (T1D participants):

        - documentation of β-cell autoimmunity and need for insulin replacement

        Exclusion Criteria:

          -  Estimated glomerular filtration rate (eGFR)&lt; 60 ml/mim

          -  25(OH)D level &lt; 20 ng/ml.

          -  Celiac disease

          -  Autoimmune thyroid disease

          -  Addison's disease

          -  History of pathological fractures

             -- Disorders associated with altered skeletal structure or function

          -  Bone active drugs in past year

          -  Diabetes of other or unclear etiology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mishaela Rubin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rukshana Majeed, BA</last_name>
    <phone>2123059489</phone>
    <email>rm3324@columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beatriz Omeragic Clinical Research Coordinator, BA</last_name>
    <phone>2123057364</phone>
    <email>bo2248@columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University Medical Center-Harkness Pavillion</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rukshana Majeed, BA</last_name>
      <phone>212-305-9489</phone>
      <email>rm3324@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Mishaela Rubin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 2, 2020</study_first_submitted>
  <study_first_submitted_qc>February 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Mishaela Rubin</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

